Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes A BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy


Autoria(s): SCHNEIDER, David J.; HARDISON, Regina M.; LOPES, Neuza; SOBEL, Burton E.; BROOKS, Maria Mori; Pro-Thrombosis Ancillary Study Grp
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

OBJECTIVE- To determine whether obesity increases platelet reactivity and thrombin activity in patients with type 2 diabetes plus stable coronary artery disease. RESEARCH DESIGN AND METHODS- We assessed platelet reactivity and markers of thrombin generation and activity in 193 patients from nine clinical sites of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Blood taken at the time of enrollment was used for assay of the concentration of prothrombin fragment 1.2 (PT1.2, released when prothrombin is activated) and fibrinopeptide A (FPA, released when fibrinogen is cleaved). Platelet activation was identified with the use of flow cytometry in response to 0, 0.2, and 1 mu mol/l adenosine diphosphate (ADP). RESULTS- Concentrations of FPA, PT1.2, and platelet activation in the absence of agonist were low. Greater BMI was associated with higher platelet reactivity in response to 1 mu m ADP as assessed by surface expression of P-selectin (r = 0.29, P < 0.0001) but not reflected by the binding of fibrinogen to activated glycoprotein IIb-IIIa. BMI was not associated with concentrations of FPA or PT1.2. Platelet reactivity correlated negatively with A1C (P < 0.04), was not related to the concentration Of triglycerides in blood, and did not correlate with the concentration of C-reactive peptide. CONCLUSIONS- Among patients enrolled in this substudy of BARI 2D, a greater BMI was associated with higher platelet reactivity at the time of enrollment. Our results suggest that obesity and insulin resistance that accompanies obesity may influence platelet reactivity in patients with type 2 diabetes.

National Heart, Lung, and Blood Institute (NHLBI/NIH)[R01 HL69146]

National Heart, Lung, and Blood Institute (NHLBI/NIH)[R01 HL71306]

NHLBI[U01 HL061746]

NHLBI[U01 HL06171748]

NHLBI[U01 HL06384]

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH)[HL061744]

Identificador

DIABETES CARE, v.32, n.5, p.944-949, 2009

0149-5992

http://producao.usp.br/handle/BDPI/21249

10.2337/dc08-1308

http://dx.doi.org/10.2337/dc08-1308

Idioma(s)

eng

Publicador

AMER DIABETES ASSOC

Relação

Diabetes Care

Direitos

restrictedAccess

Copyright AMER DIABETES ASSOC

Palavras-Chave #C-REACTIVE PROTEIN #NONDIABETIC PATIENTS #FIBRINOPEPTIDE-A #WEIGHT-REDUCTION #BLOOD #ACTIVATION #ASPIRIN #TRIAL #ATHEROSCLEROSIS #DETERMINANT #Endocrinology & Metabolism
Tipo

article

original article

publishedVersion